이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Teva Pharmaceutical Industries 미래 성장
Future 기준 확인 4/6
Teva Pharmaceutical Industries (는) 각각 연간 40.5% 및 2.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 39.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 29.1% 로 예상됩니다.
주요 정보
40.5%
수익 성장률
39.6%
EPS 성장률
Pharmaceuticals 수익 성장 | 27.6% |
매출 성장률 | 2.6% |
향후 자기자본 수익률 | 29.1% |
애널리스트 커버리지 | Good |
마지막 업데이트 | 12 Jun 2024 |
최근 미래 성장 업데이트
Recent updates
Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg
Oct 06Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price
Sep 28Teva Pharmaceutical: Past Behind And A Promising 2023
Sep 16Teva wins European approval for biosimilar to Roche’s eye therapy Lucentis
Aug 29These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt Extensively
Aug 05Teva flags supply constraints to ADHD drug Adderall as demand rises - Bloomberg
Aug 03Forex volatility, performance of generic drugs, opioid settlements in focus for Teva's Q2 earnings
Jul 26Teva again in the sights of New York Attorney General over alleged role in opioid crisis
Jul 11Teva names new medical chief
Jul 01Teva Pharma Trends Lower Ahead Of A Key Shareholder Meeting This Week
Jun 20수익 및 매출 성장 예측
날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
---|---|---|---|---|---|
12/31/2026 | 17,048 | 1,610 | 3,403 | 2,196 | 9 |
12/31/2025 | 16,625 | 1,375 | 3,097 | 2,424 | 10 |
12/31/2024 | 16,002 | 809 | 2,375 | 338 | 10 |
3/31/2024 | 16,004 | -478 | 878 | 1,389 | N/A |
12/31/2023 | 15,846 | -559 | 842 | 1,368 | N/A |
9/30/2023 | 15,273 | -2,317 | 608 | 1,157 | N/A |
6/30/2023 | 15,017 | -2,342 | 1,173 | 1,695 | N/A |
3/31/2023 | 14,925 | -1,711 | 964 | 1,494 | N/A |
12/31/2022 | 14,925 | -2,446 | 1,042 | 1,590 | N/A |
9/30/2022 | 15,141 | -1,291 | 514 | 1,073 | N/A |
6/30/2022 | 15,433 | -1,054 | 476 | 1,059 | N/A |
3/31/2022 | 15,557 | -615 | 585 | 1,154 | N/A |
12/31/2021 | 15,878 | 417 | 236 | 798 | N/A |
9/30/2021 | 16,231 | 726 | 88 | 673 | N/A |
6/30/2021 | 16,324 | -3,915 | -131 | 451 | N/A |
3/31/2021 | 16,284 | -3,982 | -94 | 506 | N/A |
12/31/2020 | 16,659 | -3,990 | 638 | 1,216 | N/A |
9/30/2020 | 16,673 | -4,031 | 902 | 1,423 | N/A |
6/30/2020 | 16,788 | 4 | 894 | 1,441 | N/A |
3/31/2020 | 17,095 | -825 | 413 | 941 | N/A |
12/31/2019 | 16,887 | -999 | 223 | 748 | N/A |
9/30/2019 | 16,396 | -4,048 | -42 | 577 | N/A |
6/30/2019 | 16,831 | -4,007 | 84 | 673 | N/A |
3/31/2019 | 17,355 | -3,559 | 449 | 1,062 | N/A |
12/31/2018 | 18,271 | -2,399 | 1,795 | 2,446 | N/A |
9/30/2018 | 19,693 | -11,059 | 2,233 | 2,938 | N/A |
6/30/2018 | 20,781 | -10,256 | 2,534 | 3,312 | N/A |
3/31/2018 | 21,800 | -16,050 | 2,750 | 3,585 | N/A |
12/31/2017 | 21,853 | -16,525 | N/A | 2,225 | N/A |
9/30/2017 | 23,479 | -5,963 | N/A | 2,791 | N/A |
6/30/2017 | 23,425 | -6,145 | N/A | 3,457 | N/A |
3/31/2017 | 22,743 | 78 | N/A | 3,985 | N/A |
12/31/2016 | 21,903 | 68 | N/A | 3,890 | N/A |
9/30/2016 | 20,292 | 1,591 | N/A | 5,415 | N/A |
6/30/2016 | 19,552 | 1,346 | N/A | 5,047 | N/A |
3/31/2016 | 19,480 | 1,697 | N/A | 5,564 | N/A |
12/31/2015 | 19,652 | 1,573 | N/A | 5,542 | N/A |
9/30/2015 | 19,939 | 1,775 | N/A | 5,679 | N/A |
6/30/2015 | 20,174 | 2,548 | N/A | 6,010 | N/A |
3/31/2015 | 20,253 | 2,757 | N/A | 5,583 | N/A |
12/31/2014 | 20,272 | 3,055 | N/A | 5,127 | N/A |
9/30/2014 | 20,534 | 2,748 | N/A | 4,191 | N/A |
6/30/2014 | 20,535 | 2,583 | N/A | 3,211 | N/A |
3/31/2014 | 20,414 | 1,383 | N/A | 3,033 | N/A |
12/31/2013 | 20,314 | 1,269 | N/A | 3,237 | N/A |
9/30/2013 | 20,133 | 1,209 | N/A | 3,998 | N/A |
6/30/2013 | 20,046 | 419 | N/A | 4,602 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: TEVA 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.4% )보다 빠른 성장으로 간주됩니다.
수익 vs 시장: TEVA (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.
고성장 수익: TEVA 향후 3년 내에 수익을 낼 것으로 예상됩니다.
수익 대 시장: TEVA 의 수익(연간 2.6% ) US 시장( 8.7% 보다 느리게 성장할 것으로 예상됩니다. 8.7% 연간).
고성장 수익: TEVA 의 수익(연간 2.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: TEVA 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 29.1 %)